Novartis: More Pain on the Way?

Can it get any worse for Novartis’ U. S. stock? The Swiss company said Tuesday that del-desiran, part of a recent acquisition, reached the end of the line in a trial for a rare neuromuscular disease. The drugmaker’s U. S. -listed shares slumped 13% to $139. 01 Tuesday.